The FDA has granted accelerated approval to sevabertinib (Hyrnuo) for the treatment of patients with locally advanced or metastatic, nonsquamous non–small cell lung cancer (NS-NSCLC) with HER2 ...
CorriXR Therapeutics announced new peer-reviewed findings showing that its CRISPR-based gene-editing approach can resensitize squamous cell lung carcinoma (LUSC) tumors to standard chemotherapy, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback